Prescription Drug Information: Labetalol Hydrochloride (Page 3 of 3)

OVERDOSAGE

Overdosage with labetalol hydrochloride causes excessive hypotension that is posture sensitive and, sometimes, excessive bradycardia. Patients should be placed supine and their legs raised, if necessary, to improve the blood supply to the brain. If overdosage with labetalol hydrochloride follows oral ingestion, gastric lavage or pharmacologically induced emesis (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. The following additional measures should be employed if necessary:

Excessive bradycardia

Administer atropine or epinephrine.

Cardiac failure

Administer a digitalis glycoside and a diuretic. Dopamine or dobutamine may also be useful.

Hypotension

Administer vasopressors, e.g., norepinephrine. There is pharmacologic evidence that norepinephrine may be the drug of choice.

Bronchospasm

Administer epinephrine and/or an aerosolized beta2 -agonist.

Seizures

Administer diazepam.

In severe beta-blocker overdose resulting in hypotension and/or bradycardia, glucagon has been shown to be effective when administered in large doses (5 mg to 10 mg rapidly over 30 seconds, followed by continuous infusion of 5 mg per hour that can be reduced as the patient improves).

Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol hydrochloride from the general circulation (less than 1%).

The oral LD50 value of labetalol hydrochloride in the mouse is approximately 600 mg/kg and in the rat is greater than 2 g/kg. The intravenous LD50 in these species is 50 mg/kg to 60 mg/kg.

DOSAGE AND ADMINISTRATION

DOSAGE MUST BE INDIVIDUALIZED. The recommended initial dosage is 100 mg twice daily whether used alone or added to a diuretic regimen. After 2 or 3 days, using standing blood pressure as an indicator, dosage may be titrated in increments of 100 mg b.i.d. (twice daily) every 2 or 3 days. The usual maintenance dosage of labetalol hydrochloride tablets is between 200 mg and 400 mg twice daily.

Since the full antihypertensive effect of labetalol hydrochloride tablets is usually seen within the first 1 to 3 hours of the initial dose or dose increment, the assurance of a lack of an exaggerated hypotensive response can be clinically established in the office setting. The antihypertensive effects of continued dosing can be measured at subsequent visits, approximately 12 hours after a dose, to determine whether further titration is necessary.

Patients with severe hypertension may require from 1200 mg to 2400 mg per day, with or without thiazide diuretics. Should side effects (principally nausea or dizziness) occur with these doses administered b.i.d. (twice daily), the same total daily dose administered t.i.d. (three times daily) may improve tolerability and facilitate further titration. Titration increments should not exceed 200 mg b.i.d. (twice daily).

When a diuretic is added, an additive antihypertensive effect can be expected. In some cases this may necessitate a labetalol hydrochloride tablet dosage adjustment. As with most antihypertensive drugs, optimal dosages of labetalol hydrochloride tablets are usually lower in patients also receiving a diuretic.

When transferring patients from other antihypertensive drugs, labetalol hydrochloride tablets should be introduced as recommended and the dosage of the existing therapy progressively decreased.

Elderly Patients

As in the general patient population, labetalol therapy may be initiated at 100 mg twice daily and titrated upwards in increments of 100 mg b.i.d. (twice daily) as required for control of blood pressure. Since some elderly patients eliminate labetalol more slowly, however, adequate control of blood pressure may be achieved at a lower maintenance dosage compared to the general population. The majority of elderly patients will require between 100 mg and 200 mg b.i.d. (twice daily).

HOW SUPPLIED

Labetalol Hydrochloride Tablets, USP, for oral administration, are available as

100 mg

Round, beige film-coated tablets, plain on one side, scored and debossed with “I/126” on the other side:

NDC 58657-602-01 bottles of 100

NDC 58657-602-50 bottles of 500

NDC 58657-602-10 bottles of 1000

200 mg

Round, white film-coated tablets, plain on one side, scored and debossed with “I/127” on the other side:

NDC 58657-603-01 bottles of 100

NDC 58657-603-50 bottles of 500

NDC 58657-603-10 bottles of 1000

300 mg

Round, blue film-coated tablets, plain on one side, and debossed with “I/130” on the other side:

NDC 58657-604-01 bottles of 100

NDC 58657-604-50 bottles of 500

NDC 58657-604-10 bottles of 1000

Labetalol Hydrochloride Tablets, USP should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure as required.

To report SUSPECTED ADVERSE REACTI ONS, contact 1-844-466-6469 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Distributed by:

Method Pharmaceuticals, LLC

Fort Worth, TX 76118

Rev. 11/2019

PRINCIPAL DISPLAY PANEL

NDC 58657-602-01
Labetalol
Hydrochloride
Tablets, USP
100 mg
Rx Only 100 Tablets

PRINCIPAL DISPLAY PANEL
NDC 58657-602-01
Labetalol 
Hydrochloride 
Tablets, USP
100 mg
Rx Only 
100 Tablets
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 58657-603-01
Labetalol
Hydrochloride
Tablets, USP
200 mg
Rx Only 100 Tablets

PRINCIPAL DISPLAY PANEL
NDC 58657-603-01
Labetalol 
Hydrochloride 
Tablets, USP
200 mg
Rx Only 
100 Tablets
(click image for full-size original)

PRINCIPAL DISPLAY PANEL

NDC 58657-604-01
Labetalol
Hydrochloride
Tablets, USP
300 mg
Rx Only 100 Tablets

PRINCIPAL DISPLAY PANEL
NDC 58657-604-01
Labetalol 
Hydrochloride 
Tablets, USP
300 mg
Rx Only 
100 Tablets
(click image for full-size original)
LABETALOL HYDROCHLORIDE labetalol hydrochloride tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58657-602
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LABETALOL (LABETALOL) LABETALOL 100 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE
CARNAUBA WAX
HYPROMELLOSES
MAGNESIUM STEARATE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
STARCH, CORN
FERRIC OXIDE RED
TITANIUM DIOXIDE
FERRIC OXIDE YELLOW
Product Characteristics
Color BROWN (beige) Score 2 pieces
Shape ROUND Size 8mm
Flavor Imprint Code I;126
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:58657-602-01 100 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:58657-602-10 1000 TABLET, FILM COATED in 1 BOTTLE None
3 NDC:58657-602-50 500 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075215 11/22/2019
LABETALOL HYDROCHLORIDE labetalol hydrochloride tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58657-603
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LABETALOL (LABETALOL) LABETALOL 200 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE
CARNAUBA WAX
HYPROMELLOSES
MAGNESIUM STEARATE
POLYETHYLENE GLYCOL, UNSPECIFIED
STARCH, CORN
TITANIUM DIOXIDE
POLYDEXTROSE
TRIACETIN
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 10mm
Flavor Imprint Code I;127
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:58657-603-01 100 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:58657-603-10 1000 TABLET, FILM COATED in 1 BOTTLE None
3 NDC:58657-603-50 500 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075215 11/22/2019
LABETALOL HYDROCHLORIDE labetalol hydrochloride tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:58657-604
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LABETALOL (LABETALOL) LABETALOL 300 mg
Inactive Ingredients
Ingredient Name Strength
ANHYDROUS LACTOSE
CARNAUBA WAX
FD&C BLUE NO. 2
HYPROMELLOSES
MAGNESIUM STEARATE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
STARCH, CORN
TITANIUM DIOXIDE
Product Characteristics
Color BLUE Score 2 pieces
Shape ROUND Size 11mm
Flavor Imprint Code I;130
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:58657-604-01 100 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:58657-604-10 1000 TABLET, FILM COATED in 1 BOTTLE None
3 NDC:58657-604-50 500 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075215 11/22/2019
Labeler — Method Pharmaceuticals, LLC (060216698)

Revised: 11/2019 Method Pharmaceuticals, LLC

Page 3 of 3 1 2 3

RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Medication Sections

Medication Information by RSS

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2019. All Rights Reserved.